Strategies for Management of Corneal Neovascularisation
Corneal Neovascularisation
About this trial
This is an interventional treatment trial for Corneal Neovascularisation
Eligibility Criteria
Inclusion Criteria:
- Patients over the age of 18
- Able to give informed consent
- With corneal neovascularisation non responsive or not suitable for conventional steroid therapy
- Use of effective contraception in females of childbearing age
Exclusion Criteria:
- Patients under 18 years of age
- Patients unable or refusing to provide informed consent
- Patients who are needle phobic
- Pregnant women, women aiming for conception and breastfeeding women
- Patients with hypersensitivity to the active substance or to any of the excipients
- Patients with active or suspected ocular or periocular infections.
- Patients with active severe intraocular inflammation.
- Patients with raised intraocular pressure or on glaucoma medication
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Fine needle Diathermy
Fine Needle Diathermy and Bevacizumab
Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels.
Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels. Patients will receive subconjunctival injections of bevacizumab in the conjunctiva near the limbus in the quadrant(s) affected (total volume of between 0.2 ml-0.3 ml of the 2.5 mg/0.1 ml solution). The subconjunctival injections will be administered after FND in the same treated quadrants.